Literature DB >> 18358479

The -8 UTR C/G polymorphism of PSMA6 gene is associated with susceptibility to myocardial infarction in type 2 diabetic patients.

Michelangela Barbieri1, Raffaele Marfella, Maria Rosaria Rizzo, Virginia Boccardi, Mario Siniscalchi, Concetta Schiattarella, Silvio Siciliano, Pietro Lemme, Giuseppe Paolisso.   

Abstract

AIMS: Controversial results have been provided regarding the potential role of proteasome subunit alpha type 6 gene (PSMA6) in determining susceptibility to myocardial infarction (MI). In addition, no data in Caucasians have been provided. We aimed to: (a) validate in a Caucasian population the association between PSMA6 gene polymorphism and MI; (b) investigate the potential association between PSMA6 gene variants and MI in type 2 diabetics; (c) evaluate a potential functional role of PSMA6 allelic variants.
METHODS: 224 subjects (73 patients with MI and 151 controls) were genotypized for variants of PSMA6 gene. In 36 patients, biopsy specimens were taken from the left ventricle area of presumed ischemia for ubiquitin-proteasome activity quantification.
RESULTS: Allele frequency and genotype distribution of all PSMA6 gene polymorphisms studied did not differ between patients with MI and controls. When the analysis was restricted to type 2 diabetics (n=119), a different rs_1048990 C/G allele frequency and genotype distribution was found having diabetic subjects with MI (n=34) higher G allele frequency compared to controls (n=85), (p=0.02). Myocardial ubiquitin levels (r=0.75; p<0.001) and proteasome 20S (r=0.7; p<0.01) activity significantly correlated with plasma glucose even after adjusting for covariates. Type 2 diabetic subjects had higher myocardial ubiquitin levels (p<0.001) and proteasome 20S activity (p<0.001) compared to non-diabetics. Subjects carriers the allele G at rs_1048990 loci had higher myocardial ubiquitin levels and proteasome 20S activity.
CONCLUSION: PSMA6 rs_1048990 polymorphism may contribute to MI susceptibility in type 2 diabetes. Up-regulation of ubiquitin-proteasome pathway may be a potential mechanism for explaining such association.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18358479     DOI: 10.1016/j.atherosclerosis.2008.01.005

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  13 in total

1.  Genetic variations in the PSMA3, PSMA6 and PSMC6 genes are associated with type 1 diabetes in Latvians and with expression level of number of UPS-related and T1DM-susceptible genes in HapMap individuals.

Authors:  Tatjana Sjakste; Natalia Paramonova; Kristine Osina; Kristine Dokane; Jelizaveta Sokolovska; Nikolajs Sjakste
Journal:  Mol Genet Genomics       Date:  2015-12-12       Impact factor: 3.291

Review 2.  On to the road to degradation: atherosclerosis and the proteasome.

Authors:  Joerg Herrmann; Lilach O Lerman; Amir Lerman
Journal:  Cardiovasc Res       Date:  2009-10-08       Impact factor: 10.787

3.  Genetic variants associated with myocardial infarction in the PSMA6 gene and Chr9p21 are also associated with ischaemic stroke.

Authors:  M G Heckman; A I Soto-Ortolaza; N N Diehl; S Rayaprolu; T G Brott; Z K Wszolek; J F Meschia; O A Ross
Journal:  Eur J Neurol       Date:  2012-08-06       Impact factor: 6.089

4.  Quantitative assessment of the influence of PSMA6 variant (rs1048990) on coronary artery disease risk.

Authors:  Hairong Wang; Mei Jiang; Hua Zhu; Qihong Chen; Peihua Gong; Jie Lin; Jide Lu; Jianping Qiu
Journal:  Mol Biol Rep       Date:  2012-10-31       Impact factor: 2.316

5.  Inhibition of ubiquitin protein expression and 20S proteasome activity by irbesartan prevents post-infarction ventricular remodeling and decreases TNF-α generation.

Authors:  Naiju Zhang; Tianping Chen; Chunfang Liu; Bi Tang; Ling Nie; Huiling An; Duilan Zhao; Li Pan; Meiling Yu
Journal:  Biomed Rep       Date:  2013-09-12

6.  PSMA6 (rs2277460, rs1048990), PSMC6 (rs2295826, rs2295827) and PSMA3 (rs2348071) genetic diversity in Latvians, Lithuanians and Taiwanese.

Authors:  Tatjana Sjakste; Natalia Paramonova; Lawrence Shi-Shin Wu; Zivile Zemeckiene; Brigita Sitkauskiene; Raimundas Sakalauskas; Jiu-Yao Wang; Nikolajs Sjakste
Journal:  Meta Gene       Date:  2014-04-17

7.  Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer.

Authors:  Tomohiko Kakumu; Mitsuo Sato; Daiki Goto; Toshio Kato; Naoyuki Yogo; Tetsunari Hase; Masahiro Morise; Takayuki Fukui; Kohei Yokoi; Yoshitaka Sekido; Luc Girard; John D Minna; Lauren A Byers; John V Heymach; Kevin R Coombes; Masashi Kondo; Yoshinori Hasegawa
Journal:  Cancer Sci       Date:  2017-04-25       Impact factor: 6.716

8.  Complex disease interventions from a network model for type 2 diabetes.

Authors:  Deniz Rende; Nihat Baysal; Betul Kirdar
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

9.  Genetics of proteasome diseases.

Authors:  Aldrin V Gomes
Journal:  Scientifica (Cairo)       Date:  2013-12-30

10.  Association between functional variant of inflammatory system gene (PSMA6) and end-stage kidney disease.

Authors:  Monika Buraczynska; Anna Stec; Aleksandra Filipczak; Andrzej Ksiazek
Journal:  Int Urol Nephrol       Date:  2016-09-26       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.